RPHM May 2024 5.000 put
| Previous Close | 3.5000 |
| Open | 3.5000 |
| Bid | 2.8000 |
| Ask | 3.6000 |
| Strike | 5.00 |
| Expire Date | 2024-05-17 |
| Day's Range | 3.5000 - 3.5000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 10 |
GlobeNewswireReneo Pharmaceuticals and OnKure Announce Proposed Merger
Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing OnKure’s portfolio of novel precision medicines in oncology Combined company is expected to have approximately $120 million of cash resources at close, which is expected to provide funding through multiple clinical milestones and runway into fourth quarter of 2026 IRVINE, Calif., and BOULDER, Colo., May 13, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM) and OnKure, Inc., a private
- GlobeNewswire
Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results
IRVINE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the first quarter ended March 31, 2024. First Quarter and Recent Highlights In December 2023, the pivotal STRIDE study of mavodelpar in adult patients with primary mitochondrial myopathies did not meet its primary e
- GlobeNewswire
Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update
IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a business update. Fourth Quarter and Recent Highlights The pivotal STRIDE study of mavodelpar in adult patients with primary mitochondrial myopathi
